-

07:33:36 PM

KURA Stock News

KURA - Kura Oncology Inc

11/24/21 6:45 AM

Nasdaq : KURA

clinical trial

Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced

RHEA-AI

neutral

11/23/21 7:30 AM

Nasdaq : KURA

conferences

Kura Oncology to Participate in Two Upcoming Investor Conferences

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer,

RHEA-AI

neutral

11/04/21 4:05 PM

Nasdaq : KURA

earnings

Kura Oncology Reports Third Quarter 2021 Financial Results

– Continued enrollment in Phase 1b study of menin inhibitor KO-539 in NPM1-mutant and KMT2A-rearranged relapsed/refractory AML – – ASH presentation to highlight molecular mechanisms of activity for KO-539 and potential for synergistic activity in combination with venetoclax – – First clinical site

RHEA-AI

positive

11/02/21 7:30 AM

Nasdaq : KURA

conferences

Kura Oncology to Participate in Credit Suisse Healthcare Conference

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Credit Suisse 30 th Annual Healthcare

RHEA-AI

neutral

10/28/21 7:30 AM

Nasdaq : KURA

conferencesearnings

Kura Oncology to Report Third Quarter 2021 Financial Results

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2021 financial results after the

RHEA-AI

neutral

10/18/21 7:30 AM

Nasdaq : KURA

management

Kura Oncology Appoints Teresa Bair as Chief Legal Officer

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Teresa Bair as Chief Legal Officer and Corporate

RHEA-AI

very positive

09/07/21 7:30 AM

Nasdaq : KURA

conferences

Kura Oncology to Participate in Two Upcoming Investor Conferences

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer,

RHEA-AI

neutral

08/05/21 4:05 PM

Nasdaq : KURA

earnings

Kura Oncology Reports Second Quarter 2021 Financial Results

– First patients dosed in Phase 1b expansion cohorts with menin inhibitor KO-539 – – Clinical collaboration with Novartis to evaluate tipifarnib in combination with the PI3Kα inhibitor alpelisib in HNSCC – – KO-2806 nominated as lead development candidate in next-generation farnesyl transferase

RHEA-AI

positive

08/04/21 7:30 AM

Nasdaq : KURA

conferences

Kura Oncology to Participate in Wedbush PacGrow Healthcare Virtual Conference

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Wedbush PacGrow Healthcare Virtual

RHEA-AI

neutral

07/29/21 4:05 PM

Nasdaq : KURA

conferencesearnings

Kura Oncology to Report Second Quarter 2021 Financial Results

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2021 financial results after the

RHEA-AI

neutral

KURA Data:

IndustryPharmaceutical Preparation Manufacturing
Websitewww.kuraoncology.com
CeoTroy Wilson
Security nameKura Oncology Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees89
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address12730 High Bluff Drive, Suite 400
StateCalifornia
CitySan Diego
Zip92130
CountryUS
Phone18585008800

KURA Description:

Tipifarnib, is a potent, selective and orally bioavailable inhibitor of farnesyl transferase in-licensed from Janssen. Previously, tipifarnib was studied in more than 5,000 cancer patients and showed compelling and durable anti-cancer activity in certain patient subsets; however, no molecular mechanism of action had been determined that could explain its clinical activity across a range of solid tumor and hematologic indications. Leveraging advances in next generation sequencing as well as emerging information about cancer genetics and tumor biology, the Company is seeking to identify those patients most likely to benefit from tipifarnib. In addition to Breakthrough Therapy Designation, tipifarnib has been granted Fast Track designation by the FDA for the treatment of patients with HRAS mutant HNSCC. In addition to HNSCC, tipifarnib has demonstrated encouraging clinical activity in a number of additional genetically defined tumor types. Kura has received multiple issued patents for tipifarnib, providing patent exclusivity in the U.S. and foreign countries. About Kura Oncology